That Which Is Claimed Is:

1. A compound having the structure represented by the formula:




wherein Cy represents a 5 or 6 member aromatic ring, B' represents an alkylene bridging moiety, Q is $(CH_2)_m$, Q' is $(CH_2)_p$, and Q" is $(CH_2)_q$ where m is 1, 2, 3 or 4, p is 0,1, 2 or 3, and q is 0, 1 or 2, and the values of m, p and q are selected such that the azabicyclic ring shown in the structure contains 6, 7, 8 or 9 members, $Z_J$ represents a non-hydrogen substituent group, j is an integer from 0 to 5, Z' represent hydrogen or lower alkyl, the dotted lines in the structure signify bonds that can be either carbon-carbon single bonds or carbon-carbon double bonds subject to the provision that only one dotted line represents a carbon-carbon double bond.

2. The compound of Claim 1 wherein Cy is:




wherein A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about –0.3 and about 0.75.

3. The compound of Claim 1 wherein Cy is




X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75, A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about –0.3 and about 0.75.

4. The compound of Claim 3 wherein X" is nitrogen.

5. The compound of Claim 3 wherein X" is selected from the group consisting of $CNO_2$, $CNH_2$, $CNHCH_3$ and $CN(CH_3)_2$.

6. The compound of Claim 3 wherein X' and X" are nitrogen.

7. The compound of Claim 3 wherein Cy represents a 3-pyridyl moiety.

8. The compound of Claim 1 selected from the group consisting of:
(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)isoxazole and
(E)- and (Z)-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)-3-methylisoxazole.

9. The compound of Claim 1 selected from the group consisting of:
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-ethoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isopropoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isobutoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-phenoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-benzyloxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxymethyl-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-phenyl-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-hydroxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-pyrimidinyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane
(E)- and (Z)-6-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane and
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 9-azabicyclo[4.2.1]nonane.

10. The compound of Claim 1 selected from the group consisting of:
2-(2-(3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-ethoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isopropoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isobutoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-phenoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-benzyloxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxymethyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-phenyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-hydroxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-pyrimidinyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane
6-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane and
2-(2-(3-pyridyl)ethynyl)- 9-azabicyclo[4.2.1]nonane.

11. The compound of Claim 1 wherein m is 1, 2 or 3.

12. The compound of Claim 1 wherein p is 0, 1 or 2.

13. The compound of Claim 1 wherein q is 0 or 1.

14. The compound of Claim 1 wherein j is 0 or 1.

15. The compound of Claim 1 wherein B' is ethylenic.

16. The compound of Claim 1 wherein B' is acetylenic.

17. The compound of Claim 1 wherein B' is a two carbon atom bridging species.

18. The compound of Claim 1 wherein j is 0; Z' is hydrogen or lower alkyl; m is 1, 2 or 3; q is 0 or 1; p is 1 or 2; and each of E' and E" is hydrogen.

19. The compound of Claim 18 wherein the sum of m and q is 3 or less.

20. The compound of Claim 1 wherein Cy is 3-pyridy, unsubstituted or substituted in the 5 and/or 6 position(s), 5-pyrimidinyl unsubstituted or substituted in the 2 position, or 3- or 5-isoxazolyl unsubstituted or substituted in the 4 and/or 5 and 3 and/or 4 positions respectively.

21. A method for treating a disorder characterized by an alternation in normal neurotransmitter release, the method comprising administering an effective amount of a compound having the structure represented by the formula:




wherein Cy represents a 5 or 6 member aromatic ring, B' represents an alkylene bridging moiety, Q is $(CH_2)_m$, Q' is $(CH_2)_p$, and Q" is $(CH_2)_q$ where m is 1, 2, 3 or 4, p is 0,1, 2 or 3, and q is 0, 1 or 2, and the values of m, p and q are selected such that the azabicyclic ring shown in the structure contains 6, 7, 8 or 9 members, $Z_j$ represents a non-hydrogen substituent group, j is an integer from 0 to 5, Z' represent hydrogen or lower alkyl, the dotted lines in the structure signify bonds that can be either carbon-carbon single bonds or carbon-carbon double bonds subject to the provision that only one dotted line represents a carbon-carbon double bond.

22. The method of Claim 21 whereby Cy is:




wherein A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about –0.3 and about 0.75.

23. The method of Claim 21 whereby Cy is




X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75, A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about –0.3 and about 0.75.

24. The method of Claim 23 whereby X" is nitrogen.

25. The method of Claim 23 whereby X" is selected from the group consisting of $CNO_2$, $CNH_2$, $CNHCH_3$ and $CN(CH_3)_2$.

26. The method of Claim 23 whereby X' and X" are nitrogen.

27. The method of Claim 23 whereby Cy represents a 3-pyridyl moiety.

28. The method of Claim 21 whereby the compound is selected from the group consisting of:

(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)-3-methylisoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)-3-methylisoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)-3-methylisoxazole

(E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)isoxazole and

(E)- and (Z)-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)-3-methylisoxazole.

29. The method of Claim 21 whereby the compound is selected from the group consisting of:

(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-methoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-ethoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-isopropoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-isobutoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-phenoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-benzyloxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-methoxymethyl-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-phenyl-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-hydroxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(5-pyrimidinyl)ethenyl)-7-azabicyclo[2.2.1]heptane

(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane

(E)- and (Z)-6-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane and

(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 9-azabicyclo[4.2.1]nonane.

30. The method of Claim 21 whereby the compound is selected from the group consisting of:

2-(2-(3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-methoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-ethoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-isopropoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-isobutoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-phenoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-benzyloxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-methoxymethyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-phenyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-hydroxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-pyrimidinyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane
6-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane and
2-(2-(3-pyridyl)ethynyl)- 9-azabicyclo[4.2.1]nonane.

31. The method of Claim 21 whereby m is 1, 2 or 3.

32. The method of Claim 21 whereby p is 0, 1 or 2.

33. The method of Claim 21 whereby q is 0 or 1.

34. The method of Claim 21 whereby j is 0 or 1.

35. The method of Claim 21 whereby B' is ethylenic.

36. The method of Claim 21 whereby B' is acetylenic.

37. The method of Claim 21 whereby B' is a two carbon atom bridging species.

38. The method of Claim 21 whereby j is 0; Z' is hydrogen or lower alkyl; m is 1, 2 or 3; q is 0 or 1; p is 1 or 2; and each of E' and E" is hydrogen.

39. The method of Claim 38 whereby the sum of m and q is 3 or less.

40. The method of Claim 21 whereby Cy is 3-pyridy, unsubstituted or substituted in the 5 and/or 6 position(s), 5-pyrimidinyl unsubstituted or substituted in the 2 position, or 3- or 5-isoxazolyl unsubstituted or substituted in the 4 and/or 5 and 3 and/or 4 positions respectively.

41. A pharmaceutical composition comprising an effective amount of a compound having the structure represented by the formula:




wherein Cy represents a 5 or 6 member aromatic ring, B' represents an alkylene bridging moiety, Q is $(CH_2)_m$, Q' is $(CH_2)_p$, and Q" is $(CH_2)_q$ where m is 1, 2, 3 or 4, p is 0,1, 2 or 3, and q is 0, 1 or 2, and the values of m, p and q are selected such that the azabicyclic ring shown in the structure contains 6, 7, 8 or 9 members, $Z_j$ represents a non-hydrogen substituent group, j is an integer from 0 to 5, Z' represent hydrogen or lower alkyl, the dotted lines in the structure signify bonds that can be either carbon-carbon single bonds or carbon-carbon double bonds subject to the provision that only one dotted line represents a carbon-carbon double bond.

42. The pharmaceutical composition of Claim 41 wherein Cy is:




wherein A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about –0.3 and about 0.75.

43. The pharmaceutical composition of Claim 41 wherein Cy is




X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75, A and A' individually are either hydrogen or suitable non-hydrogen substituent species having a sigma m value between about –0.3 and about 0.75.

44. The pharmaceutical composition of Claim 43 wherein X" is nitrogen.

45. The pharmaceutical composition of Claim 43 wherein X" is selected from the group consisting of $CNO_2$, $CNH_2$, $CNHCH_3$ and $CN(CH_3)_2$.

46. The pharmaceutical composition of Claim 43 wherein X' and X" are nitrogen.

47. The pharmaceutical composition of Claim 43 wherein Cy represents a 3-pyridyl moiety.

48. The pharmaceutical composition of Claim 41 wherein the compound is selected from the group consisting of:
(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(7-azabicyclo[2.2.1]hept-2-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)isoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-6-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)isoxazole

(E)- and (Z)-5-(2-(8-azabicyclo[3.2.1]oct-2-yl)ethenyl)-3-methylisoxazole
(E)- and (Z)-5-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)isoxazole and
(E)- and (Z)-(2-(9-azabicyclo[4.2.1]non-2-yl)ethenyl)-3-methylisoxazole.

49. The pharmaceutical composition of Claim 41 wherein the compound is selected from the group consisting of:
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-ethoxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isopropoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-isobutoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-phenoxy-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-benzyloxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-methoxymethyl-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-phenyl-3-pyridyl) ethenyl)-7-azabicyclo[2.2.1]heptane, (E)- and (Z)-2-(2-(5-hydroxy-3-pyridyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(5-pyrimidinyl)ethenyl)-7-azabicyclo[2.2.1]heptane
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane
(E)- and (Z)-6-(2-(3-pyridyl)ethenyl)- 8-azabicyclo[3.2.1]octane and
(E)- and (Z)-2-(2-(3-pyridyl)ethenyl)- 9-azabicyclo[4.2.1]nonane.

50. The pharmaceutical composition of Claim 41 wherein the compound is selected from the group consisting of:
2-(2-(3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-ethoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isopropoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-isobutoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-phenoxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-benzyloxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-methoxymethyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane

2-(2-(5-phenyl-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-hydroxy-3-pyridyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(5-pyrimidinyl)ethynyl)-7-azabicyclo[2.2.1]heptane
2-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane
6-(2-(3-pyridyl)ethynyl)- 8-azabicyclo[3.2.1]octane and
2-(2-(3-pyridyl)ethynyl)- 9-azabicyclo[4.2.1]nonane.

51. The pharmaceutical composition of Claim 41 wherein m is 1, 2 or 3.

52. The pharmaceutical composition of Claim 41 wherein p is 0, 1 or 2.

53. The pharmaceutical composition of Claim 41 wherein q is 0 or 1.

54. The pharmaceutical composition of Claim 41 wherein j is 0 or 1.

55. The pharmaceutical composition of Claim 41 wherein B' is ethylenic.

66. The pharmaceutical composition of Claim 41 wherein B' is acetylenic.

67. The pharmaceutical composition of Claim 41 wherein B' is a two carbon atom bridging species.

68. The pharmaceutical composition of Claim 41 wherein j is 0; Z' is hydrogen or lower alkyl; m is 1, 2 or 3; q is 0 or 1; p is 1 or 2; and each of E' and E" is hydrogen.

69. The pharmaceutical composition of Claim 68 wherein the sum of m and q is 3 or less.

70. The pharmaceutical composition of Claim 41 wherein Cy is 3-pyridy, unsubstituted or substituted in the 5 and/or 6 position(s), 5-pyrimidinyl unsubstituted or substituted in the 2 position, or 3- or 5-isoxazolyl unsubstituted or substituted in the 4 and/or 5 and 3 and/or 4 positions respectively.